Cargando…

Efficacy and safety of Xinmai’an tablet in treatment of premature ventricular contractions due to coronary heart disease: A protocol for systematic review and meta-analysis

Coronary heart disease (CHD) is the leading cause of human death in the world and a public health problem of global concern. As a common arrhythmia in CHD, premature ventricular contractions are very likely to progress to fatal arrhythmias, resulting in serious adverse consequences. At present, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Meiling, Che, Sihua, Pan, Weiwei, Zhang, Shumao, Shi, Guijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750681/
https://www.ncbi.nlm.nih.gov/pubmed/36626460
http://dx.doi.org/10.1097/MD.0000000000032253
_version_ 1784850309380571136
author Wang, Meiling
Che, Sihua
Pan, Weiwei
Zhang, Shumao
Shi, Guijun
author_facet Wang, Meiling
Che, Sihua
Pan, Weiwei
Zhang, Shumao
Shi, Guijun
author_sort Wang, Meiling
collection PubMed
description Coronary heart disease (CHD) is the leading cause of human death in the world and a public health problem of global concern. As a common arrhythmia in CHD, premature ventricular contractions are very likely to progress to fatal arrhythmias, resulting in serious adverse consequences. At present, the treatment of premature ventricular contractions due to CHD mainly focuses on catheter ablation, beta-blockers and antiarrhythmics. Both require ongoing monitoring because relapses may lead to redevelopment of cardiomyopathy, and there are varying degrees of indications and side effects. Several clinical studies have shown that Xinmai’an can effectively control the occurrence of premature ventricular contractions and reduce the risk of recurrence. However, there is currently no systematic review evaluating its effectiveness. Therefore, the purpose of this study is to provide strong evidence-based medical evidence for Xinmai’an tablet in the treatment of premature ventricular contractions due to CHD. METHODS: We will search the main Chinese and English databases from inception to June 5, 2022. And identified as the randomized controlled trials. In addition, a reference list of studies meeting the inclusion criteria will be retrieved. Two researchers will conduct literature screening and quality evaluation. And we will conduct bias risk assessment and sensitivity analysis. The analysis software uses RevMan 5.3. RESULTS: Mainly by observing the number of ventricular premature beat attacks (24-hour holter monitoring electrocardiogram), electrocardiogram efficacy (ST segment and T wave changes) and echocardiogram assesses the structure and function of the left and right ventricular, left ventricular ejection fraction, etc. To evaluate the clinical effect of Xinmai’an on premature ventricular contractions due to CHD. CONCLUSION: The results of this study will provide a basis for the selection of treatment options for premature ventricular contractions due to CHD.
format Online
Article
Text
id pubmed-9750681
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97506812022-12-28 Efficacy and safety of Xinmai’an tablet in treatment of premature ventricular contractions due to coronary heart disease: A protocol for systematic review and meta-analysis Wang, Meiling Che, Sihua Pan, Weiwei Zhang, Shumao Shi, Guijun Medicine (Baltimore) 3800 Coronary heart disease (CHD) is the leading cause of human death in the world and a public health problem of global concern. As a common arrhythmia in CHD, premature ventricular contractions are very likely to progress to fatal arrhythmias, resulting in serious adverse consequences. At present, the treatment of premature ventricular contractions due to CHD mainly focuses on catheter ablation, beta-blockers and antiarrhythmics. Both require ongoing monitoring because relapses may lead to redevelopment of cardiomyopathy, and there are varying degrees of indications and side effects. Several clinical studies have shown that Xinmai’an can effectively control the occurrence of premature ventricular contractions and reduce the risk of recurrence. However, there is currently no systematic review evaluating its effectiveness. Therefore, the purpose of this study is to provide strong evidence-based medical evidence for Xinmai’an tablet in the treatment of premature ventricular contractions due to CHD. METHODS: We will search the main Chinese and English databases from inception to June 5, 2022. And identified as the randomized controlled trials. In addition, a reference list of studies meeting the inclusion criteria will be retrieved. Two researchers will conduct literature screening and quality evaluation. And we will conduct bias risk assessment and sensitivity analysis. The analysis software uses RevMan 5.3. RESULTS: Mainly by observing the number of ventricular premature beat attacks (24-hour holter monitoring electrocardiogram), electrocardiogram efficacy (ST segment and T wave changes) and echocardiogram assesses the structure and function of the left and right ventricular, left ventricular ejection fraction, etc. To evaluate the clinical effect of Xinmai’an on premature ventricular contractions due to CHD. CONCLUSION: The results of this study will provide a basis for the selection of treatment options for premature ventricular contractions due to CHD. Lippincott Williams & Wilkins 2022-12-09 /pmc/articles/PMC9750681/ /pubmed/36626460 http://dx.doi.org/10.1097/MD.0000000000032253 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 3800
Wang, Meiling
Che, Sihua
Pan, Weiwei
Zhang, Shumao
Shi, Guijun
Efficacy and safety of Xinmai’an tablet in treatment of premature ventricular contractions due to coronary heart disease: A protocol for systematic review and meta-analysis
title Efficacy and safety of Xinmai’an tablet in treatment of premature ventricular contractions due to coronary heart disease: A protocol for systematic review and meta-analysis
title_full Efficacy and safety of Xinmai’an tablet in treatment of premature ventricular contractions due to coronary heart disease: A protocol for systematic review and meta-analysis
title_fullStr Efficacy and safety of Xinmai’an tablet in treatment of premature ventricular contractions due to coronary heart disease: A protocol for systematic review and meta-analysis
title_full_unstemmed Efficacy and safety of Xinmai’an tablet in treatment of premature ventricular contractions due to coronary heart disease: A protocol for systematic review and meta-analysis
title_short Efficacy and safety of Xinmai’an tablet in treatment of premature ventricular contractions due to coronary heart disease: A protocol for systematic review and meta-analysis
title_sort efficacy and safety of xinmai’an tablet in treatment of premature ventricular contractions due to coronary heart disease: a protocol for systematic review and meta-analysis
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750681/
https://www.ncbi.nlm.nih.gov/pubmed/36626460
http://dx.doi.org/10.1097/MD.0000000000032253
work_keys_str_mv AT wangmeiling efficacyandsafetyofxinmaiantabletintreatmentofprematureventricularcontractionsduetocoronaryheartdiseaseaprotocolforsystematicreviewandmetaanalysis
AT chesihua efficacyandsafetyofxinmaiantabletintreatmentofprematureventricularcontractionsduetocoronaryheartdiseaseaprotocolforsystematicreviewandmetaanalysis
AT panweiwei efficacyandsafetyofxinmaiantabletintreatmentofprematureventricularcontractionsduetocoronaryheartdiseaseaprotocolforsystematicreviewandmetaanalysis
AT zhangshumao efficacyandsafetyofxinmaiantabletintreatmentofprematureventricularcontractionsduetocoronaryheartdiseaseaprotocolforsystematicreviewandmetaanalysis
AT shiguijun efficacyandsafetyofxinmaiantabletintreatmentofprematureventricularcontractionsduetocoronaryheartdiseaseaprotocolforsystematicreviewandmetaanalysis